CD20-话题@MedSci

#CD20#

37篇内容 | 894人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1943801, encodeId=949a1943801d8, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, objectType=article, longId=187245, objectId=3b7518e245e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b7518e245e4, replyNumber=0, likeNumber=39, createdTime=2021-01-11, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b7518e245e4, moduleTitle=对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b7518e245e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943805, encodeId=7e96194380543, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=PI3Kδ抑制剂umbralisib+CD20抑制剂ublituximab用于CLL试验因疗效显著提前中止, objectType=article, longId=193716, objectId=100b193e1677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=100b193e1677, replyNumber=0, likeNumber=33, createdTime=2020-10-18, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=100b193e1677, moduleTitle=PI3Kδ抑制剂umbralisib+CD20抑制剂ublituximab用于CLL试验因疗效显著提前中止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=100b193e1677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943800, encodeId=f43b19438003d, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=Sci Rep：结直肠癌免疫治疗新发现，CD20+B淋巴细胞有效改善预后！, objectType=article, longId=185799, objectId=6aa8185e9972, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aa8185e9972, replyNumber=0, likeNumber=34, createdTime=2020-09-17, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aa8185e9972, moduleTitle=Sci Rep：结直肠癌免疫治疗新发现，CD20+B淋巴细胞有效改善预后！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aa8185e9972)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943796, encodeId=af261943e9698, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=FDA授予罗氏的CD20单抗Gazyva在狼疮性肾炎中的突破性治疗指定, objectType=article, longId=179673, objectId=1fca1e96732d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fca1e96732d, replyNumber=0, likeNumber=37, createdTime=2020-04-30, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fca1e96732d, moduleTitle=FDA授予罗氏的CD20单抗Gazyva在狼疮性肾炎中的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fca1e96732d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943804, encodeId=1ee619438048d, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, objectType=article, longId=193606, objectId=c7931936061f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7931936061f, replyNumber=0, likeNumber=38, createdTime=2021-03-03, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7931936061f, moduleTitle=加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7931936061f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943794, encodeId=553c1943e94e3, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, objectType=article, longId=178542, objectId=bc501e854207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc501e854207, replyNumber=0, likeNumber=54, createdTime=2020-06-11, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc501e854207, moduleTitle=诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc501e854207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943797, encodeId=44fb1943e97b1, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=罗氏CD20利妥昔单抗治疗寻常型天疱疮的III试验成功, objectType=article, longId=181544, objectId=65631815442f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65631815442f, replyNumber=0, likeNumber=40, createdTime=2020-07-04, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65631815442f, moduleTitle=罗氏CD20利妥昔单抗治疗寻常型天疱疮的III试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65631815442f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943792, encodeId=fc231943e92bb, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=CD20单抗在淋巴瘤治疗中仍是基石药物, objectType=article, longId=168976, objectId=dfee1689e6f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfee1689e6f2, replyNumber=0, likeNumber=44, createdTime=2019-08-17, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfee1689e6f2, moduleTitle=CD20单抗在淋巴瘤治疗中仍是基石药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfee1689e6f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943799, encodeId=00ca1943e9946, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=Diabetologia：在NOD小鼠抗cd20治疗后，表型明显的抗胰岛素B细胞在胰岛重新增殖？, objectType=article, longId=185165, objectId=014518516583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=014518516583, replyNumber=0, likeNumber=22, createdTime=2020-06-29, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=014518516583, moduleTitle=Diabetologia：在NOD小鼠抗cd20治疗后，表型明显的抗胰岛素B细胞在胰岛重新增殖？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=014518516583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943795, encodeId=bd331943e95e5, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND, objectType=article, longId=179626, objectId=eba11e962686, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba11e962686, replyNumber=0, likeNumber=38, createdTime=2019-10-04, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba11e962686, moduleTitle=Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba11e962686)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943790, encodeId=61e61943e9096, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%, objectType=article, longId=164498, objectId=282016449820, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282016449820, replyNumber=0, likeNumber=28, createdTime=2020-03-10, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282016449820, moduleTitle=新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=282016449820)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943793, encodeId=12171943e93bb, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=2019年欧洲神经病学学会（EAN）：CD20单抗Ublituximab治疗复发多发性硬化患者安全、耐受良好, objectType=article, longId=174977, objectId=d4a81e497768, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4a81e497768, replyNumber=0, likeNumber=44, createdTime=2020-01-31, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4a81e497768, moduleTitle=2019年欧洲神经病学学会（EAN）：CD20单抗Ublituximab治疗复发多发性硬化患者安全、耐受良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4a81e497768)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943791, encodeId=11cc1943e9193, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=罗氏的抗CD20单抗ocrelizumab在英国获批上市，治疗原发性进行性多发性硬化症, objectType=article, longId=165885, objectId=92ae165885e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92ae165885e9, replyNumber=0, likeNumber=38, createdTime=2020-01-17, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92ae165885e9, moduleTitle=罗氏的抗CD20单抗ocrelizumab在英国获批上市，治疗原发性进行性多发性硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92ae165885e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943788, encodeId=e4b31943e88da, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=CCCD2018丨刘新峰教授：急性缺血性卒中血管再通治疗的新进展与指南解读, objectType=article, longId=136352, objectId=719713635205, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=719713635205, replyNumber=0, likeNumber=48, createdTime=2018-12-25, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=719713635205, moduleTitle=CCCD2018丨刘新峰教授：急性缺血性卒中血管再通治疗的新进展与指南解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=719713635205)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943789, encodeId=a0f51943e897b, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=Connect Tissue Res：CD200的强表达提高了间充质基质细胞的分化能力和免疫调节功能, objectType=article, longId=138609, objectId=26a0138609e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26a0138609e9, replyNumber=0, likeNumber=37, createdTime=2018-06-29, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26a0138609e9, moduleTitle=Connect Tissue Res：CD200的强表达提高了间充质基质细胞的分化能力和免疫调节功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26a0138609e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943787, encodeId=9e571943e87d5, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=Blood：抑制HDAC6可上调CD20水平，并增强抗CD20单克隆抗体的疗效。, objectType=article, longId=110680, objectId=b97911068050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b97911068050, replyNumber=0, likeNumber=34, createdTime=2018-04-21, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b97911068050, moduleTitle=Blood：抑制HDAC6可上调CD20水平，并增强抗CD20单克隆抗体的疗效。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b97911068050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1943786, encodeId=dd211943e86b6, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, objectTitle=J immunol：CD200R信号调节肿瘤特异性T细胞免疫反应, objectType=article, longId=72370, objectId=f76fe2370ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f76fe2370ff, replyNumber=0, likeNumber=43, createdTime=2016-07-20, rootId=0, userName=aliceclz, userId=bfa6343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f76fe2370ff, moduleTitle=J immunol：CD200R信号调节肿瘤特异性T细胞免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f76fe2370ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CD20

2020-05-29

aliceclz (审核中...)

前往app查看评论内容

#CD20#

对于未经治疗的慢性淋巴细胞白血病患者，AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价

2021-01-11

aliceclz (审核中...)

前往app查看评论内容

#CD20#

PI3Kδ抑制剂umbralisib+CD20抑制剂ublituximab用于CLL试验因疗效显著提前中止

2020-10-18

aliceclz (审核中...)

前往app查看评论内容

#CD20#

Sci Rep：结直肠癌免疫治疗新发现，CD20+B淋巴细胞有效改善预后！

2020-09-17

aliceclz (审核中...)

前往app查看评论内容

#CD20#

FDA授予罗氏的CD20单抗Gazyva在狼疮性肾炎中的突破性治疗指定

2020-04-30

aliceclz (审核中...)

前往app查看评论内容

#CD20#

加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者

2021-03-03

aliceclz (审核中...)

前往app查看评论内容

#CD20#

诺华的CD20单抗Arzerra治疗多发性硬化症的两项III期试验成功

2020-06-11

aliceclz (审核中...)

前往app查看评论内容

#CD20#

罗氏CD20利妥昔单抗治疗寻常型天疱疮的III试验成功

2020-07-04

aliceclz (审核中...)

前往app查看评论内容

#CD20#

CD20单抗在淋巴瘤治疗中仍是基石药物

2019-08-17

aliceclz (审核中...)

前往app查看评论内容

#CD20#

Diabetologia：在NOD小鼠抗cd20治疗后，表型明显的抗胰岛素B细胞在胰岛重新增殖？

2020-06-29

aliceclz (审核中...)

前往app查看评论内容

#CD20#

Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND

2019-10-04

aliceclz (审核中...)

前往app查看评论内容

#CD20#

新研究显示BCL2抑制剂联合CD20单抗治疗慢性淋巴细胞白血病，缓解率达95%

2020-03-10

aliceclz (审核中...)

前往app查看评论内容

#CD20#

2019年欧洲神经病学学会（EAN）：CD20单抗Ublituximab治疗复发多发性硬化患者安全、耐受良好

2020-01-31

aliceclz (审核中...)

前往app查看评论内容

#CD20#

罗氏的抗CD20单抗ocrelizumab在英国获批上市，治疗原发性进行性多发性硬化症

2020-01-17

aliceclz (审核中...)

前往app查看评论内容

#CD20#

CCCD2018丨刘新峰教授：急性缺血性卒中血管再通治疗的新进展与指南解读

2018-12-25

aliceclz (审核中...)

前往app查看评论内容

#CD20#

Connect Tissue Res：CD200的强表达提高了间充质基质细胞的分化能力和免疫调节功能

2018-06-29

aliceclz (审核中...)

前往app查看评论内容

#CD20#

Blood：抑制HDAC6可上调CD20水平，并增强抗CD20单克隆抗体的疗效。

2018-04-21

aliceclz (审核中...)

前往app查看评论内容

#CD20#

J immunol：CD200R信号调节肿瘤特异性T细胞免疫反应

2016-07-20

科室
- - 订阅+
  - 更多科室
工具
服务